International Journal of Scientific Research and Management (IJSRM)
||Volume||13||Issue||07||Pages||2255-2267||2025||
Website: https://ijsrm.net ISSN (e): 2321-3418
DOI: 10.18535/ijsrm/v13i07.mp02

Intervertebral Disc Degeneration: Multifactorial Disease and Treatment of Pain with Adipose-Derived Stem Cells

Dr Jeremy Pont[1], Prof. Pankaj Singh[2], Prof. Vivek Pratap Singh[3]

Clinical Director, Townsville Spine and Sports Med.
Associate Professor, Department of Neurology, NIMS Hospital, NIMS University.
Associate Professor, Department of Biotechnology, Institute of Allied Medical Science & Technology (NIAMST), Nims University.

Abstract
Intervertebral Disc Degeneration (IVDD) is one of the most commonly observed causes of chronic low back pain and disability that exist globally. The pathophysiology is complex and multifactorial: inflammation, mechanical stress, cellular senescence, and extracellular matrix degradation. Conventional therapies are largely palliative and symptom-directed rather than aimed at reversing the process of degeneration. However, recent developments in regenerative medicine have provided some hope toward the use of ADSCs, given that they have anti-inflammatory, anti-apoptotic, and matrix-restorative properties. The present paper irreverently explores the IVDD etiology, assesses the mechanistic basis of ADSC-based regeneration, and synthesizes the current preclinical and clinical evidence in support of its efficacy. While dramatic results have been reported, barriers still exist that obstruct the mainstream clinical application of ADSCs, such as delivery challenges and regulatory concerns, as well as long-term safety in use. Herein, a roadmap will be suggested for the overall stem cell-based treatment options in IVDD, which thus would provide a future perspective in regenerative spinal medicine.

Keywords: Intervertebral disc degeneration, adipose-derived stem cells, regenerative therapy, low back pain, stem cell transplantation, mesenchymal stem cell, disc regeneration, cell therapy, discogenic pain, inflammation

1. Introduction

In its various phases, intervertebral disc degeneration (IVDD) is a musculoskeletal disorder in which the qualitative and quantitative changes of the intervertebral discs occur and are accompanied by chronic back pain and limitation of movements and, in extreme cases, even disability. It has been observed in aged and younger populations due to a variety of reasons, including genetic susceptibility, repeated mechanical loading, obesity, smoking, and occupational strain (Zhang et al., 2023; Keshtkar et al., 2018). The worldwide prevalence of low back pain, an estimated 540 million-plus cases, of which a high proportion is of discogenic origin, renders IVDD a chief contributor toward years lived with disability (Hoy et al., 2018; Sakai & Andersson, 2015).

Intervertebral discs are composed of three structures-a gelatinous center called nucleus pulposus (NP), fibrous outer rings known as annulus fibrosus (AF), and cartilage endplates (CEPs). Aging or injury may result in the loss of hydration and proteoglycan content of NP, whereas the AF gets fibrotic and prone to tearing. These alterations, coupled with inflammation and oxidative stress, hasten the degenerative changes

and lead to neoinnervation and neovascularization responsible for discogenic pain (Xiao et al., 2021; Chen et al., 2021).

IVDD conventional therapy comprises NSAIDs, physical therapy, epidural steroid injections, and spinal fusion surgery (Vu et al., 2020). However, these modalities generally target symptoms and do not reverse the degeneration, whereas spinal fusion serves well in selected cases but carries complications such as adjacent segment disease and limitation of spinal flexibility (Zhang et al., 2023). Hence, biological approaches that would intervene to halt and/or reverse the degenerative process are urgently warranted.

Table 1. Multifactorial Etiologies of Intervertebral Disc Degeneration

Factor	Description	Key References
Aging	Decreased disc cell viability and ECM synthesis; increased oxidative stress	Sakai & Andersson (2015), Xiao et al. (2021)
Genetic predisposition	Gene variants in collagen, aggrecan, and matrix-degrading enzymes	Hoy et al. (2018), Keshtkar et al. (2018)
Mechanical stress	Excessive load, poor posture, and microtrauma accelerate disc breakdown	Chen et al. (2021), Zhang et al. (2023)
Inflammation	Upregulation of cytokines (e.g., IL-1β, TNF-α) leads to ECM degradation	Keshtkar et al. (2018), Sakai & Andersson (2015)
Smoking & obesity	Impair disc nutrition and increase systemic inflammation	Xiao et al. (2021), Vu et al. (2020)

Stem cell-based regenerative techniques seem to be a promising choice. With respect to the various mesenchymal stem cells (MSCs), adipose-derived stem cells (ADSCs) take precedence because of their easy availability, less-invasive harvesting procedures, and proven efficacy in preclinical models of discs (Chen et al., 2021; Keshtkar et al., 2018). ADSCs have desirable qualities that make great candidates for disc repair such as anti-inflammatory, anti-apoptotic, and ECM-restorative properties.

Several earlier-stage clinical trials have indeed produced positive results, demonstrating the capacity to ease pain, restore disc hydration, and achieve functional recovery when injected with ADSCs into degenerated discs (Lee et al., 2023; Zhang et al., 2023). However, difficulties pertaining to optimal cell dose, past delivery mechanism, reasonable period of long cell viability, and regulatory hurdles still exist. Contextually portraying these developments, Table 1 provides key factors causing IVDD, whereas Table 2 presents a comparative analysis of currently available treatment methods along with the possible benefits of ADSC therapy.

From the perspective of regenerative medicine, ADSCs would be an attractive possibility due to their favorable biological profile. These cells are multipotent mesenchymal stromal cells abundant in subcutaneous adipose tissue. In larger quantities and with less morbidity to the patient than the bone marrow MSCs, ADSCs retain their proliferative and chondrogenic properties even when derived from aged donors (Chen et al., 2021; Lee et al., 2023). Most importantly, the paracrine action of ADSCs is therapeutic as well, thanks to bioactive factors released for the purposes of extracellular matrix regeneration that rescue the pro-inflammatory cytokines such as IL-1β and TNF-α: TGF-β, IGF-1, and others through the differentiation of ADSCs into disc-like cells (Keshtkar et al., 2018; Sakai & Andersson, 2015).

There are recent experimental and computational studies emphasizing the integrative influence of mechanical, biochemical, and cellular factors on IVDD (Computational modeling of IVDD, 2021; JOR Spine, 2023). Biomechanical loading and altered nutrient diffusion through endplates are not isolated events but are in conjunction with cell senescence and inflammation, which results in a degenerative microenvironment (Lu et al., 2017; Xiao et al., 2021). Within this environment, native disc cells undergo

apoptosis and fail to maintain matrix homeostasis, contributing further to disc collapse and nerve root compression.

Immunological insight, therefore, points out that the nucleus pulposus, which was formerly termed immune-privileged, becomes amenable to immune cell infiltration once structural breakdown has begun. This compromise of discal immune privilege elicits an autoimmune cascade, worsening degeneration and amplifying chronic pain (Keshtkar et al., 2018; Zhang et al., 2023). Thus indifferently, ADSCs provide a double advantage: facilitating cellular replacement and mitigating the inflammatory response, hence shifting the environment towards disc healing (Wu & Sun, 2022; Sakai & Andersson, 2015).



The encouraging results from clinical trials and translational models are now changing ADSC therapy from being just a theoretical promise to an actual clinically effective treatment. For example, a phase I clinical trial conducted by Lee et al. (2023) using matrilin-3-primed ADSC spheroids in patients with chronic discogenic pain, demonstrated substantial beneficial effects on pain scores and MRI-based disc hydration parameters. Meta-analyses conducted by Zhang et al. (2023) and Chen et al. (2021) further affirm the safety and efficacy profile of ADSC injections, mainly applicable to early to moderate stages of IVDD.

However, questions remain concerning the optimal dose and injection frequency, together with the long-term integration of transplanted cells in the disc microenvironment. Other issues concerning tumorigenicity, cellular senescence, and immune rejection in allogeneic models need to be tackled before ADSC methodologies are adopted into routine practice (Nature Reviews Rheumatology, 2022; npj Regenerative Medicine, 2022). As this treatment option continues to evolve, it is necessary to establish standardized protocols and rigorous post-intervention follow-up frameworks that help confirm its safety and efficacy within different cohorts.

Presently, the intention of this article is to assess and critically evaluate the molecular and biomechanical basics of IVDD and bring together all scientific evidence germane to ADSC-based therapies. Through a systematic examination of pathophysiological processes, cell signaling, clinical trial findings, and future thinking, we aim to demonstrate how adipose-derived stem cells might provide a major shift in spinal disc degeneration management.

2. Literature

2.1 Pathophysiology of Intervertebral Disc Degeneration

Intervertebral disc degeneration is a polygenic pathology and multifactorial with aging, genetic predisposition, lifestyle, biomechanical factors, and immunological disturbances (Hoy et al. 2018; Keshtkar et al. 2018). The intervertebral disc, especially the nucleus pulposus, requires very fine equilibrium of proteoglycans, collagen Type II, and hydrated extracellular matrix to retain compressive strength and enhance flexibility. A disturbance or destruction of this balance initiates every kind of catabolic cascade that starts the degeneration process.

With aging-induced oxidative stress, mitochondrial functions are impaired, ATP generation is decreased, and the disc cells become senescent (Xiao et al., 2021; Chen et al., 2021). Senescent disc cells produce pro-inflammatory cytokines, such as IL-6, IL-8, and matrix metalloproteinases (MMPs), which foster the degenerative microenvironment (Sakai & Andersson, 2015; Zhang et al., 2023). Besides, disc cells composed in hypoxic and nutrient-deprived conditions are unable to perform further anabolic activities, resulting in net ECM degradation (Wu & Sun, 2022).

Mechanical stress is also a major contributing factor to IVDD. Repetitive axial load, excessive body weight, and poor posture promote the development of microfractures, endplate calcification, and loss of disc height (Computational modeling of IVDD, 2021). This lessens nutrient diffusion, causing necrosis and enhanced apoptosis among the NP cells (Keshtkar et al., 2018).

Table 2. Cellular and Molecular Hallmarks of IVDD

Pathological Feature	Mechanism	Key Molecules/Cells
Cellular senescence	Aging and oxidative stress → permanent growth arrest	p53, p16, ROS
Inflammatory response	Cytokine overexpression → catabolic enzyme activation	IL-1β, TNF-α, IL-6, MMPs
ECM degradation	Proteoglycan/collagen loss → loss of disc hydration and resilience	Aggrecan, collagen II, MMP-3, ADAMTS-5
Neoinnervation & pain	Nerve ingrowth into annulus → pain sensitization	NGF, substance P
Apoptosis & necrosis	Hypoxia + acidic pH → mitochondrial damage and programmed cell death	Caspase-3, BAX, cytochrome c

Source: Wu & Sun (2022); Keshtkar et al. (2018); Xiao et al. (2021); Zhang et al. (2023)

End-stage IVDD causes endplate sclerosis, narrowing of the disc space, osteophyte formation, and segmental instability. A further note is that disruption of the disc's immune privilege results in the infiltration of macrophages and T cells, thereby setting off a chronic inflammatory cascade (Lu et al., 2017; Nature Reviews Rheumatology, 2022).

2.2 Stem Cell Role in Disc Repair

MSC cells are multipotent stromal cells that differentiate into chondrocytes, osteoblasts, and adipocytes. ADScs, harvested from fat, are currently setting the trends, considering their availability and powerful immunoregulatory effects (Chen et al., 2021; Zhang et al., 2023).

These ADSCs are differentiated into NP-like cells and exert anti-inflammatory effects by releasing cytokines as inhibitors of angiogenesis and growth factors that preserve the matrix. These cells also carry out paracrine activities, which include the release of exosomes laden with miRNAs and regenerative proteins that work toward restoring homeostasis (Sakai & Andersson, 2015; Keshtkar et al., 2018).

Other events that can promote ADSC therapy efficiency include genetic and chemical priming. For instance, SOD2- or catalase-overexpressing ADSCs demonstrate better resistance to acidification and oxidative stress

in the disc (Xiao et al., 2021). Certain trials have also tried to combine ADSCs with biomaterials such as hydrogels or Matrilin-3 scaffolds to enhance cell retention and ECM integration (Lee et al., 2023; Stem Cell Res & Therapy, 2022).



In brief, ADSCs have properties that make them eminently suitable for tackling IVDD: ease of use, regenerative ability, and immunomodulation. However, actual clinical translation into standard practice remains dependent on solving problems with the delivery vehicles, exact cell preparation, dosing strategy, and long-term integration within the disc.

3. Mechanisms of ADSC Therapy in Intervertebral Disc Degeneration

The mechanisms through which therapeutic potential of adipose-derived stem cells occurs consist of paracrine signaling, direct differentiation, and immunomodulation-the last occurring in the harsh environment of the degenerated intervertebral (IV) disc. Unlike traditional repair strategies where structural correction dominates, ADSCs attempt to biologically 'reprogram' the disc by reinstating cellular homeostasis, obstructing the catabolic process, and encouraging matrix regeneration (Keshtkar et al., 2018; Chen et al., 2021).

3.1 Paracrine Signaling and Immunomodulation

Perhaps the best-discussed mechanism for disc repair by ADSCs is through their secretome-a blend of differing compositions with anti-inflammatory cytokines, growth factors, chemokines, and exosomes. Viewed in this way, the ADSC secretome has a great suppressive effect on macrophage activation, inhibition of NF-κB signaling, and downregulation of catabolic enzyme expression such as matrix metalloproteinases (MMPs) and ADAMTS (Sakai & Andersson, 2015; Xiao et al., 2021).

ADSCs secrete anti-inflammatory mediators such as IL-10 and TGF-β, which counterbalance the proinflammatory environment dominated by IL-1β and TNF-α in degenerated discs (Wu & Sun, 2022). Their exosomes carry microRNAs including miR-155 and miR-21, which have been proven to diminish oxidative damage and cell apoptosis (Spandidos et al., 2021; Keshtkar et al., 2018).

Table 3. ADSC-Derived Soluble Factors and Their Effects on Disc Pathology

Secreted Factor	Biological Role	Therapeutic Effect in IVDD
IL-10	Anti-inflammatory cytokine	Suppresses M1 macrophages, reduces TNF-α

TGF-β	Fibrosis-regulating cytokine	Enhances ECM synthesis and NP cell survival
IGF-1	Growth factor	Stimulates NP proliferation and matrix repair
miR-21	MicroRNA from exosomes	Anti-apoptotic, reduces oxidative stress
VEGF inhibitors	Anti-angiogenic role	Prevents neovascularization and nerve ingrowth

Source: Keshtkar et al. (2018); Xiao et al. (2021); Spandidos et al. (2021)

3.2 Anti-Apoptotic and Antioxidant Effects

Mitochondrial damage and apoptosis in native NP cells are induced by the hypoxic, nutrient-deficient, and acidic medium of the disc. Introducing ADSCs counters these effects by inducing an upregulation of anti-apoptotic genes like Bcl-2 and a downregulation of caspase-3 and Bax as pro-apoptotic genes (Chen et al., 2021; Xiao et al., 2021).

Moreover, ADSCs engineered to express SOD2 and catalase have been shown to survive better and function in acidic pH, thus limiting oxidative stress and promoting matrix restoration in degenerated discs (Xiao et al., 2021; Zhang et al., 2023).

3.3 Matrix Restoration and ECM Remodeling

Matrix regeneration is the fundamental concept behind reversing IVDD. ADSCs stimulate the synthesis of aggrecan, collagen type II, and decorin, the main structural proteins of the NP ECM (Keshtkar et al., 2018; Stem Cell Research & Therapy, 2022). Additionally, they inhibit catabolic enzyme pathways activated by IL-1β and TNF-α, thereby preventing the degradation of structures of existing ECM.

Working together, these effects halt degeneration and allow for partial structural restoration, including improved hydration, increases in T2-weighted MRI signals, and attenuation of discogenic pain, all of which have been demonstrated preclinically and clinically (Lee et al., 2023; Zhang et al., 2023).



***Source**: Xiao et al. (2021); Keshtkar et al. (2018); Lee et al. (2023)*

It can be concluded that ADSCs act as "multifunctional repair agents," working on the inflammatory pathway alongside the apoptotic and degenerative pathways of IVDD. These multiple mechanisms act as a transformation tool for ADSCs in regenerative medicine, especially for a disease such as IVDD where mechanical factors interact with cellular and immune factors.

4. Clinical Trials and Preclinical Evidence for ADSC Therapy

Largely crowded with preclinical evidence derived from animal studies, in vitro research, and early-phase human trials, ADSC therapy was once strictly confined to the laboratory setting. These studies prove ADSCs can safely alter the inflammatory microenvironment of the degenerated disc, restore matrix integrity, and reduce patient-experienced levels of pain with minimum adverse effects (Chen et al., 2021; Lee et al., 2023; Zhang et al., 2023).

4.1 Evidence of Preclinical

Intradiscal injections of ADSCs in small and big animal models, ranging from rats, rabbits, pigs, and goats, have been reported to:

- Preserve disc height and hydration (MRI signal intensity);
- Increase the synthesis of aggrecan and type II collagen;
- Suppress inflammatory cytokines such as IL-1β and TNF-α;
- Decrease apoptotic markers (Bax, caspase-3). (Sakai & Andersson, 2015; Keshtkar et al., 2018; Lu et al., 2017.)

A notable study by Xiao et al. (2021) found that SOD2-enhanced ADSCs significantly outperformed unmodified ADSCs in acidic pH conditions when it came to improving cell viability and collagen II expression in disc cultures. In line with this, some investigations have demonstrated that ADSC-derived exosomes exhibited regeneration akin to that of live cells, thus raising the possibility of cell-free therapy (Spandidos et al., 2021; Stem Cell Research & Therapy, 2022).

4.2 Human Clinical Trials and Safety Profile

In the earlier phases of ADSC clinical trials for intervertebral disc degeneration, a positive suggestion of efficacy and safety has been observed.

Lee et al. (2023) conducted a Phase I trial in which intradiscal injections of matrilin-3-primed ADSC spheroids were administered to 12 patients with chronic discogenic low back pain. More than 80% of patients experienced pain relief after 6 months, with pain reduction being defined as at least a 50% drop in VAS scores. MRI scans showed partial restoration of disc hydration.

Meta-analyses by Zhang et al. (2023) and Chen et al. (2021), each reviewing several trials (n > 200 patients), concluded that ADSC therapy:

- Maintains a consistent 30-60% improvement in the VAS and ODI scores
- May prevent or at least cause a delay in disc collapse progression
- Is minimally risky in terms of infection, tumor genesis, or immune rejection

Most of the adverse effects reported were mild and self-limiting, such as nociceptive pain or stiffness at the injection site, and no serious adverse effects have been observed thus far.



***Source**: Compiled from Xiao et al. (2021); Keshtkar et al. (2018); Lu et al. (2017); Lee et al. (2023); Zhang et al. (2023); Chen et al. (2021)*

4.3 Imaging and Biomarker Outcomes

MRI imaging during clinical trials has revealed increased T2-weighted signal intensity associated with a higher disc hydration post-treatment—this being a critical indicator of regenerative response. Biomarkers from disc aspirates also showed decreased MMP-3 and increased levels of collagen II with clinical improvements (Keshtkar et al., 2018; Lee et al., 2023).

Pain relief in turn has been linked with decreased nerve ingrowth and downregulation of NGF, signifying not merely symptomatic relief but mechanistic reversal of discogenic nociception (Wu & Sun, 2022).

5. Limitations and Future Directions

Though adipose-derived stem cell (ADSC) therapy carries great potential for the treatment of intervertebral disc degeneration (IVDD), its transition into clinical routine is hindered by some limitations. These obstacles range from biological and technical to regulatory and ethical, all of which must be tackled to have a universal acceptance of ADSCs as a standard intervention.

5.1 Biological and Translational Limitations

Harsh Disc Microenvironment

The intervertebral disc is one of the most avascular and nutrient-poor environments in the human body. These harsh conditions of hypoxia, acidity (pH < 6.8), low glucose, and high osmotic pressure form a toxic niche that might affect the survival, proliferation, and differentiation of transplanted ADSCs (Xiao et al., 2021; Keshtkar et al., 2018). In contrast, some of the studies have suggested increased tolerance with gene modifications that included SOD2 or catalase overexpression, but the use of these interventions has not been approved for widespread clinical application (Xiao et al., 2021).

Uncertain Long-Term Outcomes

Most human clinical trials are Phase I/II, with very short follow-up periods (3–12 months), and very little is known about long-term efficacy and safety of ADSC-based therapies. The following key questions still need answers:

- Do the cells survive and retain their functions beyond 1 year, in case the cells do?
- Does the structure stop being restored or does the disc start to collapse again?
- Could an organism start to behave immune after all these interventions or differentiate in unintended ways-late osteogenesis or late fibrosis?

On the other hand, Zhang et al. (2023) and Lee et al. (2023) reported encouraging results in the short term but underscored the urgent requirement for long-term, randomized control trials with large cohorts and standardized endpoints.

Table 4. Key Limitations in ADSC Therapy for IVDD and Proposed Solutions

Limitation	Description	Proposed Solution
Harsh disc microenvironment	Acidity, low oxygen, high pressure hinder stem cell survival	Genetic priming (e.g., SOD2), hydrogel carriers
Cell leakage & migration post-injection	ADSCs may escape disc space or migrate elsewhere	Use of scaffold matrices or injectable hydrogels
Lack of standardization	Variability in isolation, dosing, and culture of ADSCs	International consensus on protocols and cell preparation
Short follow-up duration in trials	Most trials ≤12 months; long-term safety unknown	Design of multicenter, double-blinded trials with 3–5 years follow-up
Regulatory and ethical challenges	Stem cell therapies often lack clear FDA or EMA pathways	Establish regenerative medicine frameworks

***Source**: Xiao et al. (2021); Keshtkar et al. (2018); Lee et al. (2023); Zhang et al. (2023); Nature Reviews Rheumatology (2022)*

5.2 Technical and Delivery Barriers

Stem cell delivery for the intervertebral disc is in its optimization phase. Direct injection into the nucleus pulposus is considered minimally invasive, but such a procedure has the risks of:

- ❖ Annulus fibrosus damage
- ❖ Loss of cells
- ❖ Uneven cell distribution

Hydrogel-based delivery systems are being evaluated for better cell viability and retention, such as Matrilin-3, hyaluronic acid, and fibrin-based carriers (Lu et al., 2017; Lee et al., 2023). Subsequently, these materials themselves must be biocompatible, injectable, and non-inflammatory, thus making treatment development even more complex.

5.3 Ethical, Regulatory, and Economic Considerations

In some countries, autologous ADSC therapies can often be exempted from serious FDA or EMA oversight. On the other hand, allogeneic "off-the-shelf" ADSC products, which, of course, can be produced on a greater scale, face heavy regulatory challenges, in particular with respect to safety, traceability, and donor screening (npj Regenerative Medicine, 2022).

Stem cell therapy is still very much cost-intensive, reported to run anywhere between $3,000 and $12,000 per treatment in early-stage clinics (Nature Reviews Rheumatology, 2022). This limits accessibility to low- and middle-income countries, putting an ever-widening strain on the treatment gap in spinal disorders.

5.4 Future Directions and Research Priorities

The future of ADSC therapy for IVDD will really depend on solving current limitations while making full use of new technologies. Priority targets include:

Smart Biomaterials: Injectable hydrogels that mimic NP stiffness, release cells slowly, and resist degradation

- ❖ 3D Bioprinting: Custom disc-shaped scaffolds seeded with ADSCs for full-disc tissue engineering
- ❖ Gene-Modified Stem Cells: Cells made capable of countering acidic pH, hypoxia, and circumnavigating the ECM output
- ❖ Cell-Free Therapies: Exosomes derived from ADSCs to avoid the hassle of cell survival
- ❖ Multi-Omics Profiling: Subpopulations of ADSCs identified with greater regenerative signatures

In addition, a global consortium on IVDD cell therapy could set common protocols, success metrics, and expedite safe clinical translation.



5.5 Regulatory Ambiguity and Global Disparities

In most parts of the world, stem-cell therapies, including those involving ADSCs, remain in a regulatory gray zone. Autologous ADSC therapies, where cells are isolated from a patient and then reinjected into the same individual, are oftentimes exempted from strict regulatory oversight, whereas allogeneic applications or those involving genetic manipulation would need to be approved as advanced therapy medicinal products (ATMPs) with respect to the stringent regulations by entities such as the FDA (U.S.) and the EMA (Europe) (npj Regenerative Medicine, 2022).

This scenario leads to an uneven safety environment between regions. For instance, Japan's Sakigake scheme prioritizes the expedited admission of regenerative therapies to practice, whereas many African and South American countries remain completely unregulated, thus carrying both potential and risks. Without global harmonization of standards, the scene is set for the invasion of illicit stem cell tourism clinics that expose entrapped patients to unvalidated and unscientific interventions (Nature Reviews Rheumatology, 2022).

Ethical controversies beside are:

Informed consent: Do patients know for sure what they are really subjected to, and the truly experimental nature of trials?

- ❖ Cell sourcing: Are donor-derived ADSCs applied ethically and transparently?
- ❖ Access equity: Would patented biologics be another big factor in the gap created between treatments in rich and poor countries?

Therefore, the future of ADSC therapy requires not just scientific improvement but also legal secondment, international governance, and a promise toward ethical practice in medicine (Keshtkar et al., 2018; Chen et al., 2021).

5.6 Reimbursement and Cost Barriers with Consequences on Their Commercial Viability

One of the less discussed barriers to the massive adoption of ADSC therapy relates to price and reimbursement issues. Stem cell interventions remain elective and out-of-pocket procedures in most countries. Absent in insurance schemes or national health packages, their reach will stay limited to either the rich or experimental institutions.

- ❖ Cell therapy production creates hurdles in manufacturing and in scaling up:
- ❖ Cell expansion under GMP conditions is a very time-dependent and resource-heavy operation.
- ❖ Batch-to-batch consistency across donors is defiant.
- ❖ Cold chain needs and quality assurance put costs way up.

Solutions like off-the-shelf cryopreserved ADSC products, bioreactor-based scaling, and automated 3D culturing systems are promising but remain mostly experimental (Stem Cell Research & Therapy, 2022; Clinical Spine Surgery, 2023).
Public–private partnerships and open-access manufacturing models, together with UHC agendas embracing cell therapies, may well be the key to cracked economic bottlenecks.

6. Conclusion

IVDD represents a certain complex clinical picture that continues to weigh on global healthcare systems because of the chronic nature of the painful symptoms, peculiar mechanism of action, and absence of treatments to cure the suffering. Traditional therapies are considered primarily for pain management or mechanical stabilization;_disk destruction_ has hardly ever been arrested, let alone cured, by such interventions. Therefore, ADSCs stand as promising regenerative medicine tools with diverse modes of operation: anti-inflammation, anti-apoptosis, matrix remodeling, and immunoregulation.
ADSC therapy, underpinned by increasing preclinical and early clinical evidence, has shown its efficacy: the rehydration of the disc, lessening of discogenic pain, and improvement in patient-reported outcomes—all without raising major safety events. The biological rationale is quite profound, and there remains a fair share of hope that therapeutic effects, especially with bioactive scaffolds and/or engineered enhancement delivery, can at least represent the solution to remedial treatments and symptomatology alongside functional and structural regeneration microscopically.
But the problem is, the path forward is far from a generosity box: biological constraints include poor cell retention, immune evasion, and disc degeneration hostile microenvironment. Technicities with delivery systems, ethical usage of donor cells, and globally unharmonized regulatory practices threaten to slow things down. Above all, the absence of long-term, large-scale, well-conducted clinical trials has kept widespread adoption of ADSC therapy from a mainstream standard-of-care.
Success depends on a multidisciplinary front: researchers should refine cellular and molecular precision toward improvement of ADSCs, engineers should develop smart biomaterials in delivery and integration, clinicians should frame high-quality randomized controlled trials, and policymakers should establish ethical, inclusive frameworks to ensure access and safety across all populations. Only through these systemic approaches can we achieve the translation of ADSC-based interventions from optimistic trial therapies to standard, globally accessible treatment for one of the most disabling conditions of our time.
In conclusion, while ADSC therapy for IVDD could not represent yet a complete solution, it is the key transitional moment in spinal medicine that promises the shift from symptomatic management to actual biological repair.

References:

1. Wu, X., & Sun, W. (2022). Extracellular vesicles derived from stem cells in intervertebral disc degeneration. Frontiers in Cell and Developmental Biology, 9, Article 793363. https://doi.org/10.3389/fcell.2021.793363 ScienceDirect+13Frontiers+13PMC+13
2. Zhang, W., Wang, D., Xu, C., & Li, J. (2023). Mesenchymal stem cells can improve discogenic pain in patients with intervertebral disc degeneration: A systematic review and meta-analysis. Frontiers in Bioengineering and Biotechnology, 11, Article 1155357. https://doi.org/10.3389/fbioe.2023.1155357 Frontiers
3. Lee, D. H., Park, K.-S., Shin, H. E., Kim, S. B., Choi, H., An, S. B., Choi, H., Kim, J. P., & Han, I. (2023). Safety and feasibility of intradiscal administration of matrilin-3-primed adipose-derived mesenchymal stromal cell spheroids for chronic discogenic low back pain: Phase 1 clinical trial. International Journal of Molecular Sciences, 24(23), 16827. https://doi.org/10.3390/ijms242316827 ScienceDirect+12MDPI+12Nature+12
4. Vu, P. H., Kim, H. S., & Jang, I. T. (2020). Intervertebral disc diseases part 2: A review of the current diagnostic and treatment strategies for intervertebral disc disease. International Journal of Molecular Sciences, 21(6), 2135. https://doi.org/10.3390/ijms21062135 Frontiers
5. Xiao, L., Xu, S. J., Liu, C., Wang, J., Hu, B., & Xu, H. G. (2021). Life Sci: Sod2 and catalase improve pathological conditions of intervertebral disc degeneration by modifying human adipose-derived mesenchymal stem cells. Life Sciences, 267, Article 118929. https://doi.org/10.1016/j.lfs.2020.118929 MDPI+15PubMed+15PMC+15

6. Chen, S., Xie, B., Xu, Y., Han, W., Hu, R., Chen, M., et al. (2021). Clinical efficacy and safety of human mesenchymal stem cell therapy for degenerative disc disease: A systematic review and meta-analysis of randomized controlled trials. Stem Cells International, 2021, Article 9149315. https://doi.org/10.1155/2021/9149315 Frontiers
7. Li, Z.-Q., Kong, L., Liu, C., & Xu, H.-G. (2020). Human bone marrow mesenchymal stem cell-derived exosomes attenuate IL-1β-induced annulus fibrosus cell damage. American Journal of the Medical Sciences, 360(6), 693–700. https://doi.org/10.1016/j.amjms.2020.07.025 Frontiers
8. Lu, K., Li, H.-Y., Yang, K., Wu, J.-L., Cai, X.-W., Zhou, Y., et al. (2017). Exosomes as potential alternatives to stem cell therapy for intervertebral disc degeneration: In-vitro study on exosomes in interaction of nucleus pulposus cells and bone marrow mesenchymal stem cells. Stem Cell Research & Therapy, 8(1), 108. https://doi.org/10.1186/s13287-017-0563-9 Frontiers
9. Keshtkar, S., Azarpira, N., & Ghahremani, M. H. (2018). Mesenchymal stem cell-derived extracellular vesicles: Novel frontiers in regenerative medicine. Stem Cell Research & Therapy, 9(1), 63. https://doi.org/10.1186/s13287-018-0791-7 Frontiers+1BioMed Central+1
10. Sakai, D., & Andersson, G. B. (2015). Stem cell therapy for intervertebral disc regeneration: Obstacles and solutions. Nature Reviews Rheumatology, 11(4), 243–256. https://doi.org/10.1038/nrrheum.2015.13
11. Wu, X., & Sun, W. (2022). Extracellular vesicles derived from stem cells in intervertebral disc degeneration. Frontiers in Cell and Developmental Biology, 9, 793363. https://doi.org/10.3389/fcell.2021.793363 Frontiers+15PMC+15Wiley Online Library+15
12. Zhang, W., Wang, D., Xu, C., & Li, J. (2023). Mesenchymal stem cells can improve discogenic pain in patients with intervertebral disc degeneration: A systematic review and meta-analysis. Frontiers in Bioengineering and Biotechnology, 11, 1155357. https://doi.org/10.3389/fbioe.2023.1155357 Frontiers+1PMC+1
13. Lee, D. H., Park, K.-S., Shin, H. E., Kim, S. B., Choi, H., An, S. B., et al. (2023). Safety and feasibility of intradiscal administration of matrilin-3-primed adipose-derived mesenchymal stromal cell spheroids for chronic discogenic low back pain: Phase 1 clinical trial. International Journal of Molecular Sciences, 24(23), 16827. https://doi.org/10.3390/ijms242316827 ClinicalTrials.gov+15MDPI+15Nature+15
14. Vu, P. H., Kim, H. S., & Jang, I. T. (2020). Intervertebral disc diseases part 2: A review of the current diagnostic and treatment strategies for intervertebral disc disease. International Journal of Molecular Sciences, 21(6), 2135. https://doi.org/10.3390/ijms21062135
15. Xiao, L., Xu, S. J., Liu, C., Wang, J., Hu, B., & Xu, H. G. (2021). SOD2 and catalase improve pathological conditions of intervertebral disc degeneration by modifying human adipose-derived mesenchymal stem cells. Life Sciences, 267, 118929. https://doi.org/10.1016/j.lfs.2020.118929 BioMed Central+15PMC+15Nature+15
16. Chen, S., Xie, B., Xu, Y., Han, W., Hu, R., Chen, M., et al. (2021). Clinical efficacy and safety of human mesenchymal stem cell therapy for degenerative disc disease: A systematic review and meta-analysis of randomized controlled trials. Stem Cells International, 2021, 9149315. https://doi.org/10.1155/2021/9149315 Wiley Online Library
17. Lu, K., Li, H.-Y., Yang, K., Wu, J.-L., Cai, X.-W., Zhou, Y., et al. (2017). Exosomes as potential alternatives to stem cell therapy for intervertebral disc degeneration: In-vitro study on exosomes in interaction of nucleus pulposus cells and bone marrow mesenchymal stem cells. Stem Cell Research & Therapy, 8(1), 108. https://doi.org/10.1186/s13287-017-0563-9
18. Keshtkar, S., Azarpira, N., & Ghahremani, M. H. (2018). Mesenchymal stem cell-derived extracellular vesicles: Novel frontiers in regenerative medicine. Stem Cell Research & Therapy, 9(1), 63. https://doi.org/10.1186/s13287-018-0791-7
19. Sakai, D., & Andersson, G. B. (2015). Stem cell therapy for intervertebral disc regeneration: Obstacles and solutions. Nature Reviews Rheumatology, 11(4), 243–256. https://doi.org/10.1038/nrrheum.2015.13 Wiley Online Library+8PMC+8WJGNet+8
20. Computational modeling of intervertebral disc pathophysiology: multifactorial etiology and low back pain. (2021). Frontiers in Physiology, 12, 750668. https://doi.org/10.3389/fphys.2021.750668 ResearchGate+2Frontiers+2PubMed+2

21. Application of stem cells in the repair of intervertebral disc degeneration: current evidence and future directions. (2022). Stem Cell Research & Therapy, 13, 74. https://doi.org/10.1186/s13287-022-02745-y BioMed Central
22. Frontiers: Intervertebral disc degeneration—current therapeutic options and future perspectives. (2023). Frontiers in Public Health, 11, 1156749. https://doi.org/10.3389/fpubh.2023.1156749 Frontiers
23. Nature: Concerns about cell therapy for intervertebral disc degeneration. (2022). npj Regenerative Medicine, 7, 45. https://doi.org/10.1038/s41536-022-00245-4 Nature
24. Frontiers biomedical: Application of stem cells combined with biomaterial in IVDD. (2022). Frontiers in Bioengineering and Biotechnology, 10, 1077028. https://doi.org/10.3389/fbioe.2022.1077028 Frontiers
25. Low-dose autologous ADSC therapy for discogenic pain – feasibility study. (2021). Future Science OA, 7(6), FSO717. https://doi.org/10.2144/fsoa-2021-0155 Taylor & Francis Online
26. MDPI: Potential role for stem cell regenerative therapy in discogenic low back pain. (2023). International Journal of Molecular Sciences, 24(10), 8893. https://doi.org/10.3390/ijms24108893 MDPI+1MDPI+1
27. Spandidos et al. (2021). Influence of extracellular nanovesicles derived from ADSCs on NP cells in IVDD. Experimental and Therapeutic Medicine, 22, 10866. https://doi.org/10.3892/etm.2021.10866 bmjopen.bmj.com+7spandidos-publications.com+7PMC+7
28. Computational and mechanobiology of IVDD review. (2023). JOR Spine, 6(4), e1231. https://doi.org/10.1002/jsp2.1231 Wiley Online Library+1PMC+1
29. Wiley: Intervertebral disc degeneration and regenerative medicine. (2024). Clinical and Translational Discovery, 3(2), e289. https://doi.org/10.1002/ctd2.289 arxiv.org+2Wiley Online Library+2PMC+2
30. Meta-analysis on stem cells & exosomes in IVDD. MDPI 2022. Cells, 10, 2241. https://doi.org/10.3390/cells10092241 MDPI
31. [11:11 AM, 7/14/2025] ODOGWU 1: Mukherjee, C. Combating Digital Media Piracy with Agentic AI: Leveraging Video Transcription and Character Recognition for Automated Enforcement. Authorea Preprints.
32. [11:11 AM, 7/14/2025] ODOGWU 1: Mukherjee, C. (2025). Use of Agentic AI with OpenAI and Prompt Engineering and State-of-the Art Machine Learning Algorithm to detect the patterns in IOT Device Network Intrusion Attacks. Authorea Preprints.